Total patients
128+12%
Clinician workspace preview
Clinical review dashboard
Review patient rows, active findings, and report controls before entering the full workspace.
Reports generated
43This month
High-priority flags
17Needs review
Pending reviews
9Open queue
Patients needing review
Active findings sorted for clinician review.
| Patient | Specialty | Active medication | Gene finding | Insight | Status |
|---|---|---|---|---|---|
| Jane Smith | Personalized medicine | Sertraline | CYP2C19 Poor metabolizer | CYP2C19 and SSRI medication metabolism | high priority |
| Marcus Lee | Personalized medicine | Escitalopram | CYP2D6 Poor metabolizer | CYP2D6 and psychiatric medication metabolism | review |
| Priya Raman | Personalized medicine | Amphetamine salts | CYP2D6 Normal metabolizer | Monitor response and side-effect trends | informational |
| Eleanor Chen | Personalized medicine | Atorvastatin | CYP2C19 Intermediate metabolizer | CYP2C19 and SSRI medication metabolism | review |
| Liam O'Sullivan | Personalized medicine | Review pending | No PGx finding | Monitor response and side-effect trends | informational |
Medication review
Jane Smith
Medication
Sertraline
Gene
safety
Priority
high priority
Finding
CYP2C19 poor metabolizer on Sertraline; CPIC-linked review is clinically relevant before any medication change.
Clinician action
Verify current response and tolerability against CPIC guidance. If a medication change is clinically indicated, document rationale and recheck symptoms in 4 weeks.
Evidence
CPIC SSRI/SNRI pharmacogenomics guideline
For clinician review only. The clinician remains the final decision-maker.